Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FSQR1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,532
Award facts
- Contract value 100% obligated
- $25,532.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $25,532.04 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg capsules (120 count). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order was awarded on January 5, 2026, with an ultimate completion date of January 6, 2026, and will be performed at the vendor's Park Ridge, Illinois location.
This award represents a delivery order issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The underlying IDC, awarded on November 13, 2025, carries a $499.999 billion ceiling value and an ultimate completion date of December 31, 2036, positioning DMS Pharmaceutical Group as a critical pharmaceutical supplier for Department of Defense healthcare operations. The PPV-G GEN V program represents the DLA's broader $30.3 billion acquisition strategy to supply comprehensive pharmaceutical products and medical consumables to military healthcare facilities worldwide, and this specific delivery order fulfills part of the recurring medical supply needs under that strategic framework.
Quick answers
Who was awarded contract SPE2DR26FSQR1?
SPE2DR26FSQR1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FSQR1 worth?
The government has obligated $25,532 on SPE2DR26FSQR1.
Is contract SPE2DR26FSQR1 an order under another contract?
Yes. SPE2DR26FSQR1 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQR1 competed?
The extent of competition for SPE2DR26FSQR1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award